Skip to main content

Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy

Feb 18, 2023 10:00 am
Social Author Name
Dr. John Cush
Tweet Content
Deucravacitinib - Effective in Systemic Lupus Erythematosus A Phase II, multicenter study has demonstrated the efficacy and safety of deucravacitinib, an oral, selective, allosteric inhibitor of TYK2, in adults with active SLE. https://t.co/YS8n02BEsk https://t.co/4sBd88AhtK
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×